Valid RAC-US Exam Q&A PDF RAC-US Dump is Ready (Updated 100 Questions)
Exam Questions and Answers for RAC-US Study Guide
NEW QUESTION 34
What is the BEST approach to ensure that raw materials, services, and sub-contractors at the level of the vendors comply with GMP requirements?
- A. Ask the vendor to take responsibility.
- B. Request documentation from the sub-contractor.
- C. Document and perform audits.
- D. Request an inspection from a regulatory authority.
Answer: C
NEW QUESTION 35
What are the MOST important elements that global regulatory agencies want to know before approving a new product for sale in their countries?
- A. Safety and failure risk
- B. Safety and effectiveness
- C. Quality and failure risk
- D. Quality and effectiveness
Answer: B
NEW QUESTION 36
A protocol for a pivotal registration trial of a new product is submitted to a major regulatory authority for review and approval. The regulatory authority issues the company a written commitment that if the studies are completed as outlined in the protocol and the results meet the pre-specified criteria for efficacy and safety, the product will be approved.
During the final week of the review of the marketing application, which has fully met all pre- specified criteria, the company receives a letter from the regulatory authority stating that it no longer believes that the product will be approved based on a recent withdrawal of a similar product in another country.
What is the BEST response?
- A. Request a meeting with the regulatory authority to discuss the application.
- B. Notify the regulatory authority regarding Its obligation to honor the commitment to approve the application.
- C. Review the regulatory guidelines to determine how to proceed.
- D. Consult with the legal department to discuss the best course of action.
Answer: A
NEW QUESTION 37
At the last internal audit, a regulatory affairs professional identified a need for a corrective action for the manufacturing process. Which of the following stakeholders should be notified FIRST?
- A. Clinical affairs
- B. Quality improvement
- C. Quality assurance
- D. Regulatory agency
Answer: C
NEW QUESTION 38
A company is developing a new product for the global market. A new international guideline will recommend relevant studies in the pediatric population, and the guideline will be effective before the approval of the company's new product.
What is the BEST advice the regulatory affairs professional can provide to minimize the impact of this guideline on the successful registration of the new product?
- A. The new guideline has no impact on the current registration plan, but the company must be prepared to defend its decision.
- B. The new guideline has no impact on the current registration plan since all relevant registration studies are almost completed.
- C. The company should initiate the required pediatric studies immediately to avoid costly delays to the current registration plan.
- D. The company should consult with relevant regulatory authorities to determine the potential impact on the current registration plan.
Answer: D
NEW QUESTION 39
A manufacturer is involved in a recall event process for a plasma-derived product. From which stage should the manufacturer be able to trace back the product?
- A. Product distribution
- B. Individual plasma donation
- C. Plasma fractionation
- D. Plasma pooling
Answer: A
NEW QUESTION 40
Company X is planning to acquire the rights for a product marketed by Company Y.
As part of due diligence, what is the MOST important information the Company X regulatory affairs professional should ask senior management to request from Company Y?
- A. Clinical trial data
- B. Safety issues
- C. Intellectual properly
- D. Marketing materials
Answer: B
NEW QUESTION 41
A superiority advertising claim for a product versus its competitor's product can only be made under which of the following circumstances?
- A. In vitro studies show the product to be superior.
- B. Government survey data indicate the product is superior.
- C. Results of adequate, well-controlled comparative clinical trial show the product is superior.
- D. Results of a three-year, post-market patient survey indicate the product is superior.
Answer: C
NEW QUESTION 42
Which of the following is MOST appropriate for the purpose of lot release of biologics?
- A. Efficacy confirmation
- B. Inventory control
- C. Safety assurance
- D. Quality verification
Answer: D
NEW QUESTION 43
Company X encounters challenges in the global life cycle management of its medical devices. Which of the following Is MOST appropriate for improving product life cycle management?
- A. Identify countries where special requirements exist during the product development phase.
- B. Initiate a global submission process after all submission data are finalized.
- C. Utilize the STED template to complete global requirements.
- D. Plan regulatory approval update meetings with senior management and stakeholders.
Answer: A
NEW QUESTION 44
One month prior to the anticipated approval date for your product, the marketing application that you submitted to a major regulatory authority has become the subject of an advisory committee meeting of experts convened by the regulatory authority. The advisory committee members unanimously vote not to approve your product because of a safety concern. Two days after the advisory committee meeting, the regulatory authority requests additional information to support the safety of your product. Assuming you have no additional data to provide, which of the following would be your MOST appropriate response to the regulatory authority's request?
- A. "We have no additional information to provide at this time, but we can perform an additional analysis for a specific safety concern, if necessary."
- B. "We disagree with the advisory committee's decision because the committee neglected the thorough safety analysis that we provided."
- C. "Given the advisory committee's unanimous decision, we know that the product will not be approved, and additional data will not make any difference."
- D. "We have no additional information to provide at this time because we have already provided everything needed to support our product's approval."
Answer: A
NEW QUESTION 45
A company is developing a device-drug combination product. Which of the following should be evaluated FIRST in order to determine the applicable guidance documents?
- A. Guidance documents for the device
- B. Determination of primary mode of action
- C. Determination of product design deliverables
- D. Approved indications of the drug
Answer: C
NEW QUESTION 46
The intermediate manufacturing process was changed during development of a pharmaceutical. The change may impact the API specification. Which functional area is responsible for the final approval of the change?
- A. Regulatory
- B. Quality
- C. Analytical
- D. Production
Answer: B
NEW QUESTION 47
According to the GHTF IVD guidance, which of the following is the CORRECT classification for a blood glucose self-testing kit?
- A. Class D
- B. Class A
- C. Class B
- D. Class C
Answer: D
NEW QUESTION 48
A global company has obtained a patent in a specific country for a newly marketed product.
What would be the BEST advice In order to protect the patent in other countries?
- A. File patents of interest in target countries.
- B. Use the Madrid system.
- C. File design patents in target countries.
- D. Use the community patent system.
Answer: A
NEW QUESTION 49
A regulatory affairs professional has submitted a package for regulatory review.
According to the regulation, the regulatory authority will need to respond within 90 days of submission.
If there is no response after the deadline, what is the BEST approach?
- A. Contact the regulatory authority, ask for clarification about the delay, and demand a decision be made regarding the submission.
- B. Contact the local political representative and ask for intervention with the regulatory authority to obtain a decision regarding the submission.
- C. Contact the company legal representative in order to begin legal proceedings to enforce the regulatory authority's response time.
- D. Contact the regulatory authority, ask for clarification about the delay, and provide answers to any outstanding questions.
Answer: D
NEW QUESTION 50
Which of the following is NOT considered a serious adverse event in a cardiovascular clinical trial?
- A. Subject's hospitalization is due to an unscheduled hip operation.
- B. Subject is hospitalized due to complications of the product administration.
- C. Subject's hospitalization is prolonged during the clinical trial.
- D. Subject is hospitalized for the purpose of product administration.
Answer: D
NEW QUESTION 51
During new drug development, a new impurity in the drug substance is detected at a level of 0.12%. The intended maximum daily dose Is less than 2 g/day, and the drug Is known generally not to be toxic.
What should be done in response to identifying the impurity?
- A. Perform both identification and non-clinical qualification studies concurrently.
- B. Perform an identification study, wait until the result is available, and then consider performing a non-clinical qualification study.
- C. Perform a non-clinical qualification study, wait until the result is available, and then consider performing an identification study.
- D. Perform either an identification study or a non-clinical qualification study.
Answer: B
NEW QUESTION 52
In order to develop a global drug product, what is the MOST important environmental characteristic to consider in the country of intended use?
- A. Product requirements
- B. Product registration
- C. Product stability
- D. Product formulation
Answer: C
NEW QUESTION 53
Which question is pertinent to demonstrate a new pharmaceutical's effectiveness during evaluation by a reimbursement agency?
- A. "Has the product been approved for mor&4nan 10 years?"
- B. "Is the product an established gold standard?"
- C. "Is the product profitable for the manufacturer?"
- D. "Is the product better than currently available alternatives?"
Answer: D
NEW QUESTION 54
In which section of the ICH Common Technical Document will the overview of clinical data appear?
- A. Module 4
- B. Module 3
- C. Module 1
- D. Module 2
Answer: D
NEW QUESTION 55
A regulation change is imminent and may require further non-clinical testing on a product currently in Phase III clinical trials. What is the most appropriate action to take FIRST?
- A. Inform the company's senior management and arrange an emergency meeting
- B. Arrange for additional testing of the product at the testing facility.
- C. Consult with the company's legal department regarding options.
- D. Obtain a copy of the proposed regulation and analyze the impact.
Answer: D
NEW QUESTION 56
A company is developing a new line of products in an area that is new to the company.
What is the BEST approach?
- A. Obtain regulatory documents and history and provide the information to R&D.
- B. Summarize regulatory documents and history and provide the information to the management team.
- C. Obtain competitor research and provide the information to the management team.
- D. Ask the trade association representative to provide an overview of the new product area to the marketing team.
Answer: B
NEW QUESTION 57
......
Certification dumps - RAC Regulatory Affairs Certification RAC-US guides - 100% valid: https://www.validbraindumps.com/RAC-US-exam-prep.html
100% Pass Your RAC-US Regulatory Affairs Certification (RAC) US at First Attempt with ValidBraindumps: https://drive.google.com/open?id=1Qu-0hN80oDWM_bFtVlh_wFBfeqdsn6jd